Form 8-K - Current report:
SEC Accession No. 0000950170-24-115767
Filing Date
2024-10-21
Accepted
2024-10-21 08:47:19
Documents
14
Period of Report
2024-10-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K engn-20241016.htm   iXBRL 8-K 53185
2 EX-10.1 engn-ex10_1.htm EX-10.1 143959
3 EX-99.1 engn-ex99_1.htm EX-99.1 16731
4 GRAPHIC img7790613_0.jpg GRAPHIC 207909
  Complete submission text file 0000950170-24-115767.txt   652594

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20241016.xsd EX-101.SCH 47536
16 EXTRACTED XBRL INSTANCE DOCUMENT engn-20241016_htm.xml XML 6764
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41854 | Film No.: 241382080
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)